View Older Stories View More Recent Stories

Mar 18, 2025 09:15AM Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Feb 27, 2025 08:00AM The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Feb 24, 2025 08:02AM Lexaria Bioscience (LEXX) Reports Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Feb 24, 2025 08:00AM Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Feb 20, 2025 08:04AM Lexaria Bioscience (LEXX) Strategic Business Pursuit of DehydraTECH-Liraglutide
Feb 20, 2025 08:00AM Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Feb 11, 2025 08:03AM Lexaria Bioscience (LEXX) Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 11, 2025 08:00AM Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 6, 2025 09:42AM Lexaria Bioscience (LEXX) Biodistribution Study For DehydraTECH GLP-1 is Underway
Feb 6, 2025 09:40AM Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Feb 5, 2025 09:14AM Lexaria Bioscience (LEXX) Updates its Ongoing Human Study GLP-1-H24-4
Feb 5, 2025 09:10AM Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Jan 30, 2025 09:17AM Lexaria Bioscience (LEXX) Releases Annual Letter from the CEO
Jan 30, 2025 09:15AM Lexaria Releases Annual Letter from the CEO
Jan 24, 2025 06:39AM Lexaria Bioscience (LEXX) PT Lowered to $7 at H.C. Wainwright
Jan 22, 2025 04:09PM Lexaria Bioscience (LEXX) Files $50M Mixed Shelf
Jan 15, 2025 09:28AM Lexaria Bioscience's (LEXX) Human GLP-1 Study #5 Receives Independent Review Board Approval
Jan 15, 2025 09:20AM Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Jan 14, 2025 09:12AM Lexaria Bioscience's (LEXX) Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Jan 14, 2025 09:10AM Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Dec 23, 2024 07:10AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
Dec 19, 2024 09:05AM Lexaria's Registered GLP-1 Study #4 Begins Dosing
Dec 18, 2024 09:26AM Lexaria Bioscience (LEXX) Forms New Scientific Advisory Board
Dec 18, 2024 09:25AM Lexaria Forms New Scientific Advisory Board
Dec 17, 2024 09:11AM Lexaria Bioscience (LEXX) Appoints Michael Gibson as Chief Medical Advisor
Dec 17, 2024 09:10AM Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Dec 9, 2024 09:10AM Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Dec 2, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
Nov 30, 2024 11:00AM BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals
Nov 26, 2024 04:47PM Lexaria Bioscience (LEXX) Files for 4.55M Share Offering
Nov 26, 2024 09:22AM Lexaria Bioscience (LEXX) Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Nov 26, 2024 09:20AM Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Nov 25, 2024 09:00AM Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Nov 25, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
Nov 20, 2024 09:05AM ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Nov 14, 2024 09:12AM Lexaria Bioscience (LEXX) Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Nov 14, 2024 09:11AM Lexaria Bioscience (LEXX) Signs Contract for New DehydraTECH GLP-1 Biodistribution Study
Nov 14, 2024 09:10AM Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Nov 13, 2024 09:20AM Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Nov 7, 2024 09:15AM Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Oct 24, 2024 09:12AM Lexaria Bioscience (LEXX): Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 24, 2024 09:10AM Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 22, 2024 09:22AM Lexaria Bioscience (LEXX): Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 22, 2024 09:20AM Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Oct 16, 2024 04:00PM Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Oct 15, 2024 08:26AM Lexaria Bioscience (LEXX) Prices 1.63M Share Offering at $3.06/sh
Oct 15, 2024 08:25AM Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Oct 9, 2024 09:05AM Lexaria Bioscience's (LEXX) GLP-1 Human Pilot Study #3 Begins Dosing
Oct 9, 2024 09:05AM Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Oct 8, 2024 09:21AM Lexaria Bioscience (LEXX) Updates Current GLP-1 Market
View More Recent Stories View Older Stories